Recce locks in $30M to boost commercialisation across ASEAN region
Recce Pharmaceuticals (ASX:RCE) has secured the first tranche of a $30M debt facility to continue running skin infection...
Market Cap $7.934M
!
Corporate Spotlight
Memphasys Ltd is a listed Australian MedTech company (ASX: MEM) focussed on reproductive biotechnology. Driven by market needs, Memphasys is developing a portfolio of device, diagnostic and media products that address human and animal reproduction issues.
View the full Corporate Spotlight
Trial results prove it lifts the guy’s game in IVF
Last update - 14.52pm 17/06/2025 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 0.5¢ | Day High | 0.5¢ | Day Low | 0.4¢ | |||
| Daily Volume | 5083373 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 17 | 0.4¢ | 6196027 | 2 | 0.5¢ | 2431903 | |
Directors & Senior Management
| Dr. David Ali | Chief Executive Officer, Executive Director |
| Mr. Pablo Neyertz | Director of Finance |
| Prof. John Aitken | Research Director |
| Assoc. Prof. Hassan Bakos | Director of Operations |
| Mr. Nick Gorring | Operations Manager |
| Mr. Andrew Metcalfe | Company Secretary |
| Ms. Lindley Edwards | Non-Executive Chairman of the Board |
| Mr. Michael Atkins | Independent Non-Executive Director |
| Mr. Paul Martin Wright | Non-Executive Independent Director |
Data source: Refinitiv
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.934M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $20.37K | 5.083M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 6196027 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 2431903 | 2 |
View Market Depth
| Last trade - 11.08am 17/06/2025 (20 minute delay) ? |
|
|||||
|
Last
0.4¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.4¢ | 0.4¢ | 0.4¢ | 1100000 | ||
| Last updated 14.52pm 17/06/2025 ? | |||||
| MEM (ASX) Chart |
